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Abstract: Cardiovascular diseases (CVDs) are the leading cause of death worldwide. The 
use of stem cells to improve recovery of the injured heart after myocardial infarction (MI) 
is an important emerging therapeutic strategy. However, recent reviews of clinical trials of 
stem cell therapy for MI and ischemic heart disease recovery report that less than half of 
the trials found only small improvements in cardiac function. In clinical trials, bone mar-
row, peripheral blood, or umbilical cord blood cells were used as the source of stem cells 
delivered by intracoronary infusion. Some trials administered only a stem cell mobilizing 
agent that recruits endogenous sources of stem cells. Important challenges to improve the 
effectiveness of stem cell therapy for CVD include: (1) improved identification, recruitment, 
and expansion of autologous stem cells; (2) identification of mobilizing and homing agents 
that increase recruitment; and (3) development of strategies to improve stem cell survival 
and engraftment of both endogenous and exogenous sources of stem cells. This review is an 
overview of stem cell therapy for CVD and discusses the challenges these three areas pres-
ent for maximum optimization of the efficacy of stem cell therapy for heart disease, and new 
strategies in progress.
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Introduction
The recovery of function after a myocardial infarction (MI) is dependent on increas-
ing blood flow and regeneration of tissue. Stem cells (SCs) can provide cellular pre-
cursors for cardiomyocyte differentiation, endothelial and supporting cells, as well 
as signals for activation of cells and prevention of apoptosis. The results of clinical 
trials have been encouraging, however either no change or only small increments 
in recovery were found. Recent reviews of completed clinical trials (2002–2010) 
for SC therapy report improvements of 10% or less in about half of the studies.1–4 
In the review by George,1 13 studies of SC therapy for acute MI were described. In 
the eight randomized controlled studies, bone-marrow (BM) cells were administered 
by intracoronary injection and left ventricular ejection fraction (LVEF) measured 
3–6 months following the MI. In five of the randomized controlled trials, there was 
only an average increase of 6% (3%–12%) in cardiac function. Mozid et al2 reported 
two additional studies of BM SC therapy for acute MI,5,6 and only one study showed 
improvement (5%) of LVEF function. Mozid et al2 also described eight clinical trials 
of SC therapy for chronic ischemic heart failure. There was improvement in LVEF 
in three of the four studies in patients treated with BM SCs and improvement in two 
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of the four studies in patients transplanted with autologous 
skeletal myoblasts. Wen et al4 performed a meta-analysis of 
eight randomized controlled trials and concluded that BM 
cell therapy provided only moderate (6%–10%) but definite 
improvements in LVEF. SC therapy has the potential to pro-
vide gains not only for MI, but also for chronic ischemia and 
heart failure. Currently, there are 33 ongoing clinical trials 
described on the ClinicalTrials.gov Website7 (see Table 1). 
While autologous BM cells are still the major source of SCs 
in the ongoing studies, new SC sources are rigorously being 
investigated. SC therapy for cardiovascular disease (CVD) is 
an intensive area of research, and collective improvements 
in the source and number of SCs, and better mobilizing and 
homing agents, are needed to increase the effectiveness of 
this emerging therapy.
Challenges for SC therapy
Improved identification and expansion  
of autologous SCs and their role  
in cardiac recovery
In the 1960s, Till et al,8 while studying the components 
responsible for regenerating blood cells, defined two required 
properties of SCs: (1) self-renewal – the ability to go through 
numerous cycles of cell division while maintaining the undif-
ferentiated state; and (2) potency – the capacity to differentiate 
into specialized cell types. SCs are identified by their capacity 
to form colonies in culture and by cell surface markers that 
are cell specific. The majority of clinical trials of SC therapy 
for heart disease have used BM cells, particularly the mono-
nuclear cells (MNCs) (Figure 1). In the ongoing trials listed 
Table 1 Ongoing clinical trials of stem-cell therapy for heart diseases
Condition Stem cells Phase Acronym ClinicalTrials.gov NCTID
Congestive heart failure Skeletal myoblasts II/III MARVEL NCT00526253
Old MI Skeletal myoblasts II PERCUTANEO NCT00908622
Angina, coronary disease Bone marrow II NCT01214499
Ischemic heart disease Bone marrow II NCT00690209
CAD, AMI Bone marrow I/II REPAIR-ACS NCT00711542
MI, ischemia Bone marrow I/II NCT01267331
AMI Bone marrow II/III REGEN-AMI NCT00765453
CAD Bone marrow II/III NCT00130377
Chronic ischemic heart failure Bone marrow II/III REGEN-IHD NCT00747708
MI Bone marrow/AC 133 III NCT01167751
Congestive heart failure Bone marrow I/II NCT01061580
Non-ischemic dilated  
cardiomyopathy
Bone marrow I/II POSEIDON-DCM NCT01392625
Dilated cardiomyopathy Bone marrow II NOGA-DCM NCT01350310
Cardiomyopathy Bone marrow II REGENERATE-DCM NCT01302171
Ischemic heart failure Bone marrow/PBC III ESCAPE NCT00841958
Left ventricular dysfunction Bone marrow II TIME NCT00684021
Left ventricular dysfunction MSC, bone marrow I/II TAC-HFT NCT00768066
Ischemia, left ventricular  
dysfunction
MSC I/II MESAMI NCT01076920
MI Mesenchymal precursors I/II NCT00555828
AMI, heart failure MSC III ESTIMATION NCT01394432
Chronic ischemic heart disease MSC II MyStromalCell NCT01449032
Congestive heart failure MSC I/II NCT00644410
Dilated cardiomyopathy CD34+ II NCT00629018
AMI CD133+ SELECT-AMI NCT00529932
MI CD133+ II/III NCT01187654
MI, CAD CD133+ I/II PERFECT NCT00950274
CAD CD133+ III NCT01049867
MI, heart failure CD133+ II IMPACT-CABG NCT01033617
AMI Adipose tissue-derived II/III ADVANCE NCT01216995
Heart failure Cardiac progenitor I TICAP NCT01273857
Congestive heart failure Cardiac I ALCADIA NCT00981006
MI Cardiosphere I CADUCEUS NCT00893360
CAD, congestive heart failure Cardiac I SCIPIO NCT00474461
Source: ClinicalTrials.gov website.7 
Abbreviations: AMI, acute myocardial infarction; CAD, coronary artery disease; MI, myocardial infarction; MSC, mesenchymal stem cell; PBC, peripheral-blood cell.
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in Table 1, other types of SCs are being tested, including 
specific BM, CD34+ or CD133+, and mesenchymal cells. 
One study tests adipose tissue-derived SCs, and three trials 
are testing cardiac progenitor/stem cells.
Skeletal myoblasts
Skeletal myoblasts isolated from muscle biopsies were the 
first cells used for the SC therapy for cardiac recovery.9 In 
a comparison of rats with chronic MI, treated with human 
skeletal myoblasts or BM-derived CD133+ progenitors, 
improvements in cardiac function were similar with the 
two cell types.10,11 In trials of skeletal myoblast treatment3 
in patients with chronic ischemic heart failure, there were 
improvements in LVEF in two of four studies (SEISMIC, 
TOPCARD-CHD).3 While the initial evaluation in clinical 
studies of skeletal myoblast treatment showed there was 
improved function, the effect was not sustained, and the cells 
were not electrically integrated into the heart.12 Enthusiasm 
for this approach has waned. However, second-generation 
products are now being developed.9,13 Six trials of skeletal 
myoblast therapy have been discontinued, but currently 
there are two active trials with skeletal myoblasts (Table 1) 
for patients with an old MI (PERCUTANEO) or congestive 
heart failure (MARVEL).
Hematopoietic progenitor/stem  
cells (HPSCs)
In clinical trials for MI or ischemic heart disease, BM, 
peripheral blood (PB), or umbilical cord blood (UCB) have 
been used as the source of SCs.1,3 Autologous BM and PB 
have an advantage over UCB cells since UCB cells may be at 
risk for immunological rejection. However, the UCB have 
a high proliferation potential.12 Autologous BM cells from 
aging individuals may have reduced transplant efficiency, 
and UCB cells would be advantageous.14,15 A limitation of the 
PB is the low yield of SCs. BM is the major source of adult 
SCs and the best characterized. The BM cells have long been 
used in therapeutic BM replacement for blood diseases.16–18 
BM SCs provide the myeloid and lymphoid lineages that 
give rise to blood cells.19 The cell surface markers that 
identify hematopoietic SCs (HSCs) for humans include: 
CD34+, CD59+, Thy1/CD90+, CD38lo/−, c-kit/CD117+, 
and lin−. There are differences in mouse HSC markers; 
namely, CD34lo/−, Sca-1+, Thy1.1+/lo, and CD38+, but 
with c-kit+ and lin− as common markers. The lineage 
negative designation includes the absence of 13–14 cell 
surface markers found on mature cells. BM has been the 
major source of SCs for reported and ongoing clinical trials. 
Currently, studies are underway that isolate subsets of the 
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Figure 1 Types of stem cells in use for heart disease therapy.1–7
Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2011–2012. All Rights Reserved.
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BM cells such as CD34+, and CD133+ for use in therapy. 
Whether these subsets of SCs will have an advantage in heart 
disease recovery remains to be seen.
Endothelial SCs
Stages of lineage development of endothelial SCs and 
their sites of origin are less well defined than those for the 
hematopoietic lineage.20 The endothelial progenitor cells 
(EPCs) found in the PB are thought to originate in the BM 
from a subset of SCs or from the myeloid precursors. There 
is considerable controversy with regard to the identification 
of the EPCs.21 Some investigators have identified the EPCs 
as CD34+ cells and/or CD133+ cells,22 while others view 
these cells as HPSCs.23,24 Recently,25,26 a consensus definition 
of EPC markers was suggested for cross-study comparisons 
and with the cell surface markers CD31+, CD34 bright, and 
CD45, AC133, CD14, CD14a, CD235a, Live/Dead Violet 
negative. Of importance for identification of the EPC is the 
ability to become endothelial cells (ECs) in culture. While 
CD34+ and/or CD133+ cells in culture may become ECs, 
the CD34+ and/or CD133+ cells could be a mixture of sub-
populations. However, the cells identified as CD34+ and/or 
CD133+ may be more effective in providing paracrine factors 
and stimulating neovascularization than the commonly used 
BM MNCs. Tongers et al27 recently described the results of a 
clinical trial for patients with refractory angina treated with 
intramyocardial autologous CD34+ cells, finding significant 
improvements in angina frequency and exercise tolerance. 
There is one clinical trial currently underway for treatment 
with CD34+ in patients with dilated cardiomyopathy, and five 
clinical trials underway for the treatment of MI, CAD, and 
heart failure with CD133+ cells. One study, NCT01187654, 
will compare the treatment of CD133+ cells and BM MNC 
in MI patients. This comparison could be informative as 
to whether the CD133+ cells have an advantage over the 
more frequently used BM MNC. Bissels et al28 found that 
microRNAs were expressed differentially in CD133+, 
CD34+, and CD133- cells involved in differentiation, pre-
vention of apoptosis, and cytoskeletal remodeling.
Mesenchymal SCs (MSCs)
The MSCs are found in the BM and other tissues. MSCs 
are positive for CD44, CD73, CD90 (Thy1), and CD105, 
and negative for the hematopoietic markers, CD45, lineage 
markers, EC (CD31), and macrophage (CD11b/MAC-1).29 
The MSCs have advantages over HSCs.27,30 Compared with 
HSCs, MSCs are more abundant, readily proliferate in cul-
ture, and are easily differentiated into different cell types, 
such as adipocytes, fibroblasts, osteocytes, and myoblasts. 
Further, studies suggest that MSCs may be more potent 
for cardiac repair than HPSCs.31 Although the MSCs can 
be differentiated into cardiomyocytes, immortalization 
was important and could increase the potential of tumor 
  formation.15 In addition to BM, adipose tissue can also be 
used as an abundant source of MSCs.32,33 The MSCs from 
UCB, adipose tissue, and BM expressed the same cell surface 
markers; however, there are some differences in the percentage 
of certain markers and colony heterogeneity. Gaebel et al34 
compared treatment of MI in mice with MSCs from UCB, 
adipose tissue, and BM. Cells from BM, adipose tissue, and 
UCB CD105+ showed improvements in heart functions, 
decreased infarct size, and capillary density. UCB CD105 
treated mice had reduced collagen deposition compared with 
BM and adipose tissue cells, and BM and UCB CD105 cells 
additionally had reduced apoptosis when compared with mice 
treated with adipose tissue cells. This study suggests that the 
function of the MSCs may be dependent on the source. Clini-
cal trials with MSCs35–37 are promising, and currently there are 
19 clinical trials underway.7,38 In a recent randomized, double 
blind, placebo-controlled study37 with MSC therapy after acute 
MI; there was improvement in the global assessment of cardiac 
function at 6 months in 45% of the patients.
Cardiac progenitor cells (CPCs)
Although it had been believed for a long time that cardiac 
myocytes were terminally differentiated, dividing myocytes 
found in the heart implied that there are resident or noncardiac 
cardiomyocyte progenitor cells.39 There have been intensive 
efforts to identify the cardiomyocyte stem and progenitor 
cells in the last 10 years.39 Purified cardiomyocytes isolated 
from rodent hearts dedifferentiate and divide, expressing SC 
markers such as c-kit, Sca-1, Isl1, and Abcg2.40–45 CPCs have 
been isolated from human myocardial biopsies.46,47 These 
same cells can organize into spheres and re-differentiate into 
myocytes and ECs.48 Yamada et al49,50 suggested that CD133+ 
cells from brown adipose tissue were highly effective in dif-
ferentiation into cardiomyocytes compared with HPSCs, and 
that mouse BAT CD133+ cells efficiently induced BM SCs 
into cardiomyocytes (CD45- CD31- CD105+) differentiation. 
There are four ongoing clinical studies to test autologous 
CPCs (Table 1); one study (ALCADIA) will use cardiac-
derived SCs to treat ischemic cardiomyopathy, and two 
studies will take advantage of the cardiosphere-derived stem/
progenitor cells (derived from cell outgrowth of autologous 
cardiac biopsy) for patients with a recent MI (CADUCEUS) 
or heart failure (TICAP). In the SCIPIO trial, patients with 
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ischemic cardiomyopathy are treated with c-kit+lin− CPCs 
derived from the right atrial appendage, and initial results 
from 16 patients report that LVEF increased and infarct 
size decreased.51
Adipose tissue-derived SCs (ASCs)
Cells isolated from adipose tissue can be separated by cen-
trifugation into adipocytes and stromal vascular cells. The 
stromal vascular fraction may contain preadipocytes, peri-
cytes and EPCs, adult multipotent MSCs, circulating blood 
cells, fibroblasts, ECs, smooth-muscle cells, and immune 
cells. This stromal vascular fraction may differentiate into a 
number of cell lineages, including the adipocytes, cartilage, 
bone skeletal muscle, neuronal cells, ECs, cardiomyocytes, 
and smooth-muscle cells.52,53 ASCs are defined as CD44 and 
CD105 positive, and Cd11b, CD34, and CD45 negative cells. 
Although there is disagreement regarding the capacity of 
ASCs to differentiate into ECs, freshly isolated human ASCs 
also consist of EPCs (CD11b, CD34, and CD45 positive cells) 
and when cultured they have a cobblestone appearance and 
take up acetylated low-density lipoprotein. Bai et al54 found 
that human freshly isolated adipocytes or cultured adipose 
tissue-derived cells underwent cardiomyogenesis through a 
fusion-independent pathway. Takahashi et al55 reported that 
in rat femoral artery injury, ASCs did not differentiate into 
ECs, but were able to inhibit neointimal formation by the 
secretion of paracrine factors. There is one ongoing clinical 
trial (NCT01216995) testing adipose tissue-derived cells in 
patients after an acute MI.
Induced pluripotent stem (iPS) cells
Another potential source of SCs is iPS cells.56 This source   
relies on in vitro de-differentiation of adult cells to 
embryonic-like SCs and then reprogramming using specific 
culture conditions to induce cardiac lineage cells including 
cardiomyocytes, smooth-muscle cells, and ECs. Adult cells 
most commonly used for iPS cells are fibroblasts and may 
be derived from a variety of tissues such as dermal, liver, 
stomach, pancreas, and neural and hematopoietic cells. 
Endogenous non-BM SC and iPS cells have been charac-
terized in animal models and some have been identified in 
adult humans. Defining these cells and their requirements 
for proliferation and mobilization will provide additional 
options for enhanced efficacy of SC therapy.
Embryonic SCs (ESCs)
The ESCs are the ideal SCs, due to the fact that cultures of 
embryonic cells when stimulated can develop into .200 
adult cell types.38,57,58 Current efforts focus on   establishing 
the conditions for directed differentiation of cells by 
altering the chemical composition of the culture medium, alter-
ing the culture surface, or inserting genes.58 A major challenge 
is the potential of uncontrolled differentiation when injected 
directly into an animal, and the potential for tumor formation. 
The promise of ESCs is to genetically modify lethal debilitat-
ing chronic disease. There are currently four clinical trials in 
progress of human ESCs for spinal cord injury and macular 
degeneration, but unfortunately none for cardiac disease.38
Expansion of SCs
A critical step for improved SC therapy is the expansion of 
accessible SCs (Figure 2). The homing of cells to injured tis-
sues is very inefficient, and increasing the number of cells that 
are available for treatment would be beneficial. Autologous 
BM cells, adipose tissue, myocardial, and UCB are cultured 
ex vivo to increase the number of cells. Culturing the tissue 
also allows selection of specific cells. The ESCs and iPS cells 
require additional steps prior to expansion of a preparation. 
The iPS cells require de-differentiation as an initial step and 
then both iPS cells and ESCs are induced to differentiate prior 
to expansion. SCs in culture form colonies, and proliferation 
without differentiation requires a specific sequence and tim-
ing of the availability of growth factors and cytokines.59–66 
In addition, these cells must maintain their pluripotency. Cells 
need to be free of feeder-cells, serum proteins, and microbial 
agents. Large-scale expansion with maintenance of pluripo-
tency and transplant safety is required.58,67   Currently, effec-
tive cell culture proliferation is limited,61 and further studies 
are needed to understand the requirements for   expansion. 
New approaches are being investigated including the use 
of nanofibers with growth factors, mesenchymal stromal 
cells in cultures of HSCs, and genetic manipulation of UCB 
HSCs.68–72 To improve SC therapy, improved methods of SC 
ex vivo expansion are required.
Identify mobilizing agents  
with improved effectiveness
SC niches
Intensive studies are underway to identify new sources of 
stem and progenitor cells for therapy. In addition to BM, 
SC niches have been identified (Figure 3) in heart. The SC 
niches are defined as a microenvironment with one or more 
SC that regulates self-renewal and progeny in vivo.73,74 Self-
renewal occurs in all tissues and in addition to BM, niches 
of SCs have been identified in heart, arteries, veins, gonads, 
intestine, epidermal tissue, and neural tissue.73,75–77 The 
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non-BM SCs were initially defined by   immunofluorescence 
in tissue, but given the number of markers needed, this 
became untenable, and isolation and identification of SCs 
by flow cytometry using multiple markers simultaneously 
has made it possible to isolate and investigate the function 
of these cells. Recently, lineage mapping has been utilized 
to locate niches in animal models by genetically labeling 
SC markers and identifying their location in adult tissue.78,79 
An example of lineage mapping is the recent study of 
Tamura et al78 of neural crest-derived SCs found in the heart 
that migrate and differentiate into cardiomyocytes after MI. 
The lineage mapping has been utilized for locating SC 
niches in a variety of developing organisms.79 The number 
of quiescent SCs is small, and better detection methods are 
necessary. Further, identifying the regulation and recruitment 
of these endogenous SCs in adults is critical.
Mobilization of BM SCs
In the BM, SCs reside in an endosteal niche along with stromal 
cells, mesenchymal cells, and ECs. The SCs are retained in 
the BM with high concentrations of stromal-derived factor 
(SDF)-1, the major chemoattractant for SCs. The SDF-1 SC 
receptor, CXCR4, is found in low concentrations. Stimula-
tion with cytokines or growth factors may interrupt ligand/
receptor balance. With a decrease in SDF-1 and an increase in 
CXCR4 expression, a signaling gradient with the PB allows 
the egress of the SCs from the BM (Figure 4). Granulocyte 
colony-stimulating factor (G-CSF) is widely used clinically 
for SC mobilization and sometimes in conjunction with 
other factors57,80 including granulocyte-macrophage colony-
stimulating factor, stem cell factor, fms-like tyrosine kinase 
(Flt)-3 ligand, and interleukin-1, -3, -6, -7, -8, -11, and -12 
(Figure 3). AMD3100, an inhibitor that blocks SDF-1 bind-
ing to CXCR4; CTCE-0021, a CXCR4 agonist; recombinant 
human growth hormone, a pleiotrophic cytokine; parathyroid 
hormone; pegfilgrastim, pegylated G-CSF with a prolonged 
half-life, and thrombopoietin, a cytokine that regulates mega-
karyocytopoiesis, are also being investigated.80
In addition to cytokines and growth factors, proteases 
such as neutrophil elastase, cathespin G, plasmin, and matrix 
metalloproteinase (MMP)-9 have been implicated in BM SC 
mobilization.81–86 After G-CSF treatment, these proteases 
increase in BM as well as in plasma; however, studies83 in 
mice deficient in neutrophil elastase or cathespin G suggest 
Embryonic
Stem cell therapy
stem cells
Cardiomyocytes
Endothelial cells
Smooth muscle cells
Hematopoietic stem cells Mesenchymal stem cells Fibroblasts
Adipocytes
(adult cells)
Cardiac stem cells
Skeletal myoblasts
stem cell
EXPANSION OF STEM CELLS
DEDIFFERENTIATE
(IPS)
DIFFERENTIATE
PROLIFERATE
Figure 2 Expansion of stem cells.
Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2011–2012. All Rights Reserved.
Notes: Currently, increased numbers of autologous hematopoietic, mesenchymal, cardiac, endothelial, and skeletal stem cells can be generated by expansion in culture with 
proliferation specific conditions. Adult cells such as fibroblasts or adipocytes may be dedifferentiated in culture to stem cells (iPS cells). MSCs, iPS cells, and ESCs can be 
induced to differentiate and proliferate in cell culture. Use of differentiated MSCs, iPS cells, and ESCs is in preclinical development.
Abbreviations: ESC, embryonic stem cell; iPS, induced pluripotent stem; MSC, mesenchymal stem cell.
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these two proteases are not required for HPSC   mobilization. 
The results of studies81,83,87,88 in MMP-9 deficient mice are 
not consistent. While some studies83,88 report MMP-9 is 
not required, other studies81,86,87 suggest MMP-9 plays an 
important role. These differences may be due to the differ-
ences in genetic background of the mice and to differences 
in the dose of the mobilizing agent. In a recent study,86 the 
authors of this present paper report that plasmin/MMP-9 is a 
major proteolytic pathway required for SC mobilization from 
BM (Figure 5). Plasmin activation of MMP-9 regulates the 
SDF-1/CXCR4 signaling. In addition, plasmin also promotes 
direct degradation of the ECM during SC mobilization.85 
G-CSF induced HSC MMP-9 degrades BM SDF-1.83,89,90 The 
increase in the number of SC mobilized with G-CSF treat-
ment may not be sufficient for the cardiac remodeling after 
MI, and some patients are resistant to G-CSF.91–93 AMD3100, 
an inhibitor of CXCR4, is a promising HSC mobilizer under 
clinical investigation. Studies report mild and reversible side 
effects94–96 and that it works synergistically with G-CSF to 
increase CD34+ cells and total white blood count.94,96–98 
However, Dai et al recently reported that chronic AMD100 
exacerbates cardiac dysfunction after MI in mice.99
Mobilization of CPCs
A number of cardiomyocyte progenitor pools have been 
identified76 that have common and unique markers, includ-
ing: side population (SP) CPCs; c-kit+ CPCs; Sca-1+ CPCs; 
cardiospheres and cardiosphere-derived cells; stage specific-
embryonic antigen-1+ (SSEA-1+) CPCs; LIM-homeodomain 
transcription factor+ (Islet-1+) CPCs; and epicardium-derived 
cells. The CPCs demonstrate greater proliferation potential 
in the infarct border compared with the necrotic core. These 
cells have the potential to differentiate into cardiomyocytes, 
smooth-muscle cells, and ECs, but the stimulatory factors for 
differentiation vary. The SP CPCs100,101 can be stimulated by 
SDF-1 and are both c-kit and Sca-1 positive, but are also posi-
tive for the ATP-binding cassette transporter (ABCG2). The 
cardiac SP cells are a mixture of subpopulations, and proof that 
these cells are SC is not definitive. The c-kit marker was used to 
identify and isolate HSCs, but their ability to differentiate into 
cardiomyocytes is controversial.102,103 Cells positive for c-kit 
isolated from human and rodent ti  ssue express specific cardiac 
transcription factors, GATA4, GATA5, MEF2C, and Kkx2, 
and when cultured express mature cardiomyocyte markers, 
cardiac actinin, cardiac myosin, desmin, and connexin 43.45,104 
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Figure 3 Stem cell mobilization and homing. Growth factors and cytokines stimulate the mobilization of the stem cells from their niche to injured tissue.
Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2011–2012. All Rights Reserved.
Notes: Flt-ligand is a growth factor; interleukins refer to interleukin-1, -3, -6, -7, -8, -11, and -12 cytokines; homing factors MCP-3, GRO-1, HGF, FGF-2, and IGF-1 are produced 
in the heart and promote endogenous and exogenous stem cells homing to the injured tissue; survival and implantation of stem cells in the tissue may result in differentiation, 
secretion of paracrine factors, and/or stimulation of angiogenesis to restore blood flow and remodel tissue.
Abbreviations: G-CSF, granulocyte colony-stimulating factor; Gm-CSF, granulocyte-macrophage colony-stimulating factor; SCF, stem cell factor/c-kit ligand; SDF-1, stromal 
cell-derived factor 1; MCP-3, monocyte chemotactic protein-3; GRO-1, growth regulated oncogene 1; HGF, hepatic growth factor; FGF-2, fibroblast growth factor; IGF-1, 
insulin-like growth factor.
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The CPCs may be stimulated by insulin-like growth factor-1 
(IGF-1); hepatic growth factor (HGF) high-mobility group box 
protein-1 (HMGB1), a chromatin-binding protein secreted by 
necrotic cells, and SDF-1.105 The CPCs possess growth factor 
receptors and when activated increase proliferation, migration, 
and differentiation. Tamoxifen-treated double-transgenic mice48 
expressed dedifferentiated cardiomyocytes that expressed 
CPC markers and ∼2/3 expressed c-kit. Studies in zebrafish 
and mammalian development suggest the potential of the 
epicardium-derived cells, the epithelial cells in the outermost 
layer of the heart, to develop into cardiomyocytes in vivo.106 
Smart et al107 reported that in mouse heart, thymosin β4 can 
release the quiescent EPDCs. Development of small molecules 
to release the cells is underway.106 Isl1+ CPCs are prominent 
during development, and in the postnatal rat, mouse, and human 
myocardium, Isl1+, c-kit-, Sca-l-, and CD31- cells have been 
defined as cardioblasts. Both iPS cells and ESCs give rise to 
this lineage in vivo. The Isl-1+ cells are rare in the myocar-
dium and the possibility of endogenously recruiting or in vitro 
expansion appears to be limited. The SSEA-1+ CPCs108 give 
rise to myocardial and endocardial cells during development 
in the neonatal and adult rat heart, but can progress to more 
committed c-kit+, Sca-1, and abcg2+ cells. When transplanted 
into rat heart, improved regeneration of infarcted myocardium 
results. Sca-1+ CD31+ cells are found in the heart as small 
interstitial cells that lack the HSC lineage markers of c-kit, Flt-
1, Flk-1, CD45, and CD34.41 Using transgenic mice, cardiac 
Sca-1+ cells were found to play a role in the regulation the 
signaling required for efficient myocardial regeneration.42,109 
Studies with ESCs and their requirements for cardiomyocyte 
differentiation may shed light on the factors that induce differ-
entiation and proliferation of the endogenous CPCs.110 A better 
understanding of SC mobilization from cardiogenic niches may 
lead to more effective agents for not only recruiting cells for 
ex vivo expansion, but to mobilize endogenous sources.
Strategies for improving SC 
homing, survival, and engraftment 
in the injured heart
SC delivery
Available routes of SC delivery include intravenous, intracoro-
nary, epicardial, endocardial, and coronary sinus injection.2,111 
While the intravenous injection of SCs is the least   invasive 
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method of delivery, retention of cells in the lungs is 
  problematic. After an MI, intracoronary injection through a 
catheter is the preferred method of delivery. The epicardial 
and transendocardial are more invasive, but the most reliable. 
The transendocardial administration uses a percutaneous 
catheter-based approach. The coronary sinus delivery pro-
vides access to the infarcted and ischemic tissue, but may 
not be available to all patients. In the clinical trials, SCs were 
delivered by either bolus or multiple intracoronary injections, 
but only a small percentage reached the heart.1,112 At least 
90% of injected cells die by apoptosis. Alternative methods of 
delivery are being investigated, such as use of  biodegradable 
scaffold-based engineered tissue.113,114 An advantage is the 
variable size, but problematic issues are thickness of the 
patch and toxicity of the degraded material. Only limited 
improvement in cardiac function has been noted. A recent 
study115 tested sheets of cardiomyocytes progenitor cell and 
reported an increase in cardiogenesis and improved function. 
The development of safe and more effective materials for use 
in SC delivery is necessary.
Homing
Homing is the migration of SCs from endogenous and exogenous 
sources through the blood or tissue to a destination where they 
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differentiate and replace or repair injured tissue. After an MI, 
expression of several factors has been observed, including tran-
sient increases in cardiac cytokines, SDF-1, MCP-3, GRO-1, 
that are chemo-attractants for SCs.116–123 After acute MI, the 
expression of these factors leads to SC homing to the infarcted 
tissue. However, many of the homing factors are expressed for 
only a short period of time after MI. SDF-1, the most studied 
homing factor, is expressed by the injured cardiac tissue for 
less than 1 week123 and MCP-3 for less than 10 days after MI.124 
In preclinical studies, genetic engineering of these factors 
into delivered SCs is effective in increasing SC homing.123,125 
For example, the delivery of SDF-1 to the myocardium, either 
through cell-based gene therapy,123,126 gene transfer,127 or protein-
enhanced128 homing of SCs, results in revascularization and 
improvement in cardiac function. Furthermore, overexpress-
ing SDF-1 receptor CXCR4 in SCs leads to greater homing of 
SCs and improved left ventricular function when the cells were 
delivered within 24 hours of MI.129–131 Studies in animals show 
that engineering cells to induce the expression of SC homing 
factors or their receptors in myocardial tissue can promote 
SC homing from BM to the injured myocardium; however, 
these have not to date been tested in humans.132
Survival/engraftment
Survival and engraftment of SCs is perhaps the most impor-
tant challenge for SC therapy, and the factors necessary for 
effective survival and engraftment are not necessarily the 
same as those required for homing. After an MI, there is an 
enormous loss of cardiomyocytes and supporting cells that 
need to be replaced. The environmental signals that may 
guide SCs to the cardiomyocyte lineage or to the secretion 
of paracrine factors may be absent in the infarcted tissue, and 
SCs may provide these signals. Many studies have focused 
on strategies to optimize SC migration through injured myo-
cardial tissue. Proteases, adhesion molecules, and integrins 
are important in regulating SC migration through injured 
myocardial tissue and modulation of the connective tissue 
microenvironment to improve SC engraftment.133–136
Several proteases have been identified to have significant 
effects on SC mobilization or SC migration and engraftment 
in cardiac tissue. SDF-1 and other factors induce the secre-
tion of matrix metalloproteinase MMP-2 and MMP-9.137–139 
Of significant interest, proteolytic enzymes, including neu-
trophil elastase, cathepsin G, and MMP-2/9, also negatively 
regulate cell migration by cleaving the N-terminal region 
of SDF-1 or cleaving CXCR4.90,139–142 Those proteolytic 
enzymes are involved in spatial temporal changes in the 
locomotion machinery of SCs, thus mediating SC recruit-
ment and engraftment.
Integrins are also key factors for adhesion, rolling and 
transmigration of SCs across the endothelium. The HSCs 
express several adhesion molecules including multiple inte-
grins. In particular, a dominant role for the α4β1 integrin 
very-late antigen [VLA]-4 interaction with vascular cell 
adhesion molecule (VCAM)-1 has been suggested by stud-
ies in which exposure to blocking antibodies to VLA-4 or 
VCAM-1 significantly reduced the engraftment of transplanted 
HSCs.143–145 CD18 expression by the EPCs is necessary for its 
interaction with EC surface ICAM-1, and a CD18 neutral-
izing antibody significantly inhibits SC engraftment after 
acute MI.146 These studies suggest the potential targets for the 
genetic enhancement of SC recruitment and engraftment.
Several other strategies have been proposed: identifying 
natural mediators; pre-translational directed differentiation of 
SCs to cardiomyocytes; activation of growth factors (FGF-2, 
IGF-1a)132 and antiapoptotic factors (p-Akt, SDF-1, BCl-1, 
and PDGF); and genetically engineered SCs.125,132 The chal-
lenge to improve survival in SC therapy is to identify effective 
ways to increase the number of cells that reach and survive 
in the injured heart area.
Assessment of SC therapy
The goals of SC therapy are to: replace lost cardiomyocytes; 
increase ECs to improve blood flow; provide paracrine cytok-
ines and growth factors; and improve measurable cardiac 
function, including an increase in LVEF; decrease left ventric-
ular end-diastolic diameter; increase myocardial perfusion; 
and importantly increase exercise capacity. In clinical trials, 
methods to measure cardiac function include echocardiog-
raphy, single photon emission computed tomography, and 
magnetic resonance imaging (MRI).1,3,37,147–149 These methods 
are well established, but more sensitive methods are neces-
sary to evaluate SC homing and engraftment. Techniques to 
evaluate the timing and specific role of narrow populations 
of cells, such as MRI150–152 and SC labeling with genetic153,154 
and immunofluorescence detectable tags155 are being inves-
tigated in animal models. The lineage/fate mapping110,156–158 
has proved to be an informative tool, and further studies in 
animal models and ex vivo SC labeling of cells for therapy 
will continue to be valuable.
Conclusion
SC therapy is an exciting and dynamic area of research with 
the potential to improve recovery of CVD, the leading cause of 
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death. While animal models clearly show benefits of SC therapy 
to improve cardiac function after MI and ischemic heart failure, 
clinical trials have been disappointing. However, the results 
of clinical trials are promising. Better methods are needed 
to improve the isolation and identification of SCs, increase 
ex vivo expansion of SCs, and increase delivery effectiveness. 
A clearer understanding of mobilization and homing of SCs is 
needed to identify new and more effective agents.   Delineating 
the function of specific SCs in remodeling injured tissue 
and how resident cardiac SCs may be enhanced is needed to 
improve SC engraftment and survival.
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